Literature DB >> 24141721

miR-661 downregulates both Mdm2 and Mdm4 to activate p53.

Y Hoffman1, D R Bublik2, Y Pilpel3, M Oren2.   

Abstract

The p53 pathway is pivotal in tumor suppression. Cellular p53 activity is subject to tight regulation, in which the two related proteins Mdm2 and Mdm4 have major roles. The delicate interplay between the levels of Mdm2, Mdm4 and p53 is crucial for maintaining proper cellular homeostasis. microRNAs (miRNAs) are short non-coding RNAs that downregulate the level and translatability of specific target mRNAs. We report that miR-661, a primate-specific miRNA, can target both Mdm2 and Mdm4 mRNA in a cell type-dependent manner. miR-661 interacts with Mdm2 and Mdm4 RNA within living cells. The inhibitory effect of miR-661 is more prevalent on Mdm2 than on Mdm4. Interestingly, the predicted miR-661 targets in both mRNAs reside mainly within Alu elements, suggesting a primate-specific mechanism for regulatory diversification during evolution. Downregulation of Mdm2 and Mdm4 by miR-661 augments p53 activity and inhibits cell cycle progression in p53-proficient cells. Correspondingly, low miR-661 expression correlates with bad outcome in breast cancers that typically express wild-type p53. In contrast, the miR-661 locus tends to be amplified in tumors harboring p53 mutations, and miR-661 promotes migration of cells derived from such tumors. Thus, miR-661 may either suppress or promote cancer aggressiveness, depending on p53 status.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24141721      PMCID: PMC3890952          DOI: 10.1038/cdd.2013.146

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  31 in total

1.  The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1.

Authors:  Yael Aylon; Yaara Ofir-Rosenfeld; Norikazu Yabuta; Eleonora Lapi; Hiroshi Nojima; Xin Lu; Moshe Oren
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

2.  Plectin promotes migration and invasion of cancer cells and is a novel prognostic marker for head and neck squamous cell carcinoma.

Authors:  Koji Katada; Takeshi Tomonaga; Mamoru Satoh; Kazuyuki Matsushita; Yurie Tonoike; Yoshio Kodera; Toyoyuki Hanazawa; Fumio Nomura; Yoshitaka Okamoto
Journal:  J Proteomics       Date:  2011-12-30       Impact factor: 4.044

Review 3.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

Review 4.  MicroRNAs in the p53 network: micromanagement of tumour suppression.

Authors:  Heiko Hermeking
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

5.  Expression signatures of TP53 mutations in serous ovarian cancers.

Authors:  Marcus Q Bernardini; Tsukasa Baba; Paula S Lee; Jason C Barnett; Gregory P Sfakianos; Angeles Alvarez Secord; Susan K Murphy; Edwin Iversen; Jeffrey R Marks; Andrew Berchuck
Journal:  BMC Cancer       Date:  2010-05-26       Impact factor: 4.430

6.  HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.

Authors:  Laëtitia K Linares; Arnd Hengstermann; Aaron Ciechanover; Stefan Müller; Martin Scheffner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-24       Impact factor: 11.205

7.  MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions.

Authors:  Sirigiri Divijendra Natha Reddy; Suresh B Pakala; Kazufumi Ohshiro; Suresh K Rayala; Rakesh Kumar
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

Review 8.  The microcosmos of cancer.

Authors:  Amaia Lujambio; Scott W Lowe
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

Review 9.  p53 and its mutants in tumor cell migration and invasion.

Authors:  Patricia A J Muller; Karen H Vousden; Jim C Norman
Journal:  J Cell Biol       Date:  2011-01-24       Impact factor: 10.539

10.  mdm2 expression is induced by wild type p53 activity.

Authors:  Y Barak; T Juven; R Haffner; M Oren
Journal:  EMBO J       Date:  1993-02       Impact factor: 11.598

View more
  45 in total

Review 1.  microRNAs and Alu elements in the p53-Mdm2-Mdm4 regulatory network.

Authors:  Yonit Hoffman; Yitzhak Pilpel; Moshe Oren
Journal:  J Mol Cell Biol       Date:  2014-06       Impact factor: 6.216

Review 2.  The regulation of MDM2 oncogene and its impact on human cancers.

Authors:  Yuhan Zhao; Haiyang Yu; Wenwei Hu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2014-01-03       Impact factor: 3.848

Review 3.  MicroRNAs in the pathobiology of sarcomas.

Authors:  Anne E Sarver; Subbaya Subramanian
Journal:  Lab Invest       Date:  2015-06-29       Impact factor: 5.662

4.  Regulatory module involving FGF13, miR-504, and p53 regulates ribosomal biogenesis and supports cancer cell survival.

Authors:  Débora R Bublik; Slađana Bursać; Michal Sheffer; Ines Oršolić; Tali Shalit; Ohad Tarcic; Eran Kotler; Odelia Mouhadeb; Yonit Hoffman; Gilad Fuchs; Yishai Levin; Siniša Volarević; Moshe Oren
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-19       Impact factor: 11.205

Review 5.  MDM4 alternative splicing and implication in MDM4 targeted cancer therapies.

Authors:  Jin Wu; Guanting Lu; Xinjiang Wang
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

6.  CircPDE7B/miR-661 axis accelerates the progression of human keloid fibroblasts by upregulating fibroblast growth factor 2 (FGF2).

Authors:  Fenglian Wu; Hongbin He; Yanxin Chen; Donglai Zhu; Tao Jiang; Jiaxin Wang
Journal:  Mol Cell Biochem       Date:  2022-01-25       Impact factor: 3.396

Review 7.  The Complex Interaction between P53 and miRNAs Joins New Awareness in Physiological Stress Responses.

Authors:  Camilla Capaccia; Silvana Diverio; Danilo Zampini; Gabriella Guelfi
Journal:  Cells       Date:  2022-05-13       Impact factor: 7.666

Review 8.  The Roles of MDM2 and MDMX in Cancer.

Authors:  Orit Karni-Schmidt; Maria Lokshin; Carol Prives
Journal:  Annu Rev Pathol       Date:  2016-03-17       Impact factor: 23.472

9.  Rare germline copy number deletions of likely functional importance are implicated in endometrial cancer predisposition.

Authors:  Gemma L Moir-Meyer; John F Pearson; Felicity Lose; Rodney J Scott; Mark McEvoy; John Attia; Elizabeth G Holliday; Paul D Pharoah; Alison M Dunning; Deborah J Thompson; Douglas F Easton; Amanda B Spurdle; Logan C Walker
Journal:  Hum Genet       Date:  2014-11-09       Impact factor: 4.132

Review 10.  MicroRNAs are critical regulators of senescence and aging in mesenchymal stem cells.

Authors:  Matthew L Potter; William D Hill; Carlos M Isales; Mark W Hamrick; Sadanand Fulzele
Journal:  Bone       Date:  2020-10-03       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.